Search - tctmd.com

Displaying 1 - 20 of 172

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Michael O'Riordan

February 07, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

L.A. McKeown

January 10, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

Todd Neale

November 28, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Daily News

Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits

Michael O'Riordan

October 03, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Michael O'Riordan

June 28, 2024

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

News Daily News

GLP-1 Receptor Agonists Come With Broad Array of Benefits, Risks

Todd Neale

January 21, 2024

News Daily News

No Signs of Hypoglycemia Causing CVD in CAROLINA and CARMELINA

Michael O'Riordan

January 05, 2024

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Majority of US Adults Have High Long-term Risk of CVD: NHANES

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

Top General Cardiology and Prevention News of 2024

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Think You Need a Statin? AHA’s Risk Calculator May Disagree

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

Statins Effective For Primary Prevention in Old and Very Old

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

GLP-1 Receptor Agonists Come With Broad Array of Benefits, Risks

No Signs of Hypoglycemia Causing CVD in CAROLINA and CARMELINA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content